Education
About Us
Working with TipRanks
Follow Us
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD)
ASX:RMD
Total Valuation
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has a market cap or net worth of AU$55.35B. The enterprise value is AU$57.29B.
Market CapAU$55.35B
Enterprise ValueAU$57.29B
Share Statistics
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has 1,459,663,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,459,663,000
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 19.56%.
Return on Equity (ROE)0.23
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)19.56%
Return on Capital Employed (ROCE)0.24
Revenue Per Employee515.66K
Profits Per Employee140.35K
Employee Count9,980
Asset Turnover0.63
Inventory Turnover2.25
Valuation Ratios
The current PE Ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is 25.0. Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s PEG ratio is 0.75.
PE Ratio25.0
PS Ratio7.38
PB Ratio6.36
Price to Fair Value6.36
Price to FCF23.01
Price to Operating Cash Flow19.89
PEG Ratio0.75
Income Statement
In the last 12 months, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh had revenue of 5.15B and earned 1.40B in profits. Earnings per share was 0.96.
Revenue5.15B
Gross Profit3.05B
Operating Income1.69B
Pretax Income1.68B
Net Income1.40B
EBITDA1.92B
Earnings Per Share (EPS)0.96
Cash Flow
In the last 12 months, operating cash flow was 1.88B and capital expenditures -119.41M, giving a free cash flow of 1.76B billion.
Operating Cash Flow1.88B
Free Cash Flow1.76B
Free Cash Flow per Share1.21
Dividends & Yields
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh pays an annual dividend of AU$0.092, resulting in a dividend yield of 0.91%
Dividend Per ShareAU$0.092
Dividend Yield0.91%
Payout Ratio23.23%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change-0.05%
50-Day Moving Average39.32
200-Day Moving Average38.98
Relative Strength Index (RSI)45.76
Average Volume (3m)1.08M
Important Dates
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh upcoming earnings date is Jan 22, 2026, After Close (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateJan 22, 2026
Ex-Dividend Date―
Financial Position
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh as a current ratio of 3.44, with Debt / Equity ratio of 13.83%
Current Ratio3.44
Quick Ratio2.53
Debt to Market Cap0.02
Net Debt to EBITDA-0.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has paid 276.84M in taxes.
Income Tax276.84M
Effective Tax Rate0.17
Enterprise Valuation
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh EV to EBITDA ratio is 19.56, with an EV/FCF ratio of 22.79.
EV to Sales7.31
EV to EBITDA19.56
EV to Free Cash Flow22.79
EV to Operating Cash Flow21.48
Balance Sheet
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has AU$1.38B in cash and marketable securities with AU$846.35M in debt, giving a net cash position of AU$537.50M billion.
Cash & Marketable SecuritiesAU$1.38B
Total DebtAU$846.35M
Net CashAU$537.50M
Net Cash Per ShareAU$0.37
Tangible Book Value Per ShareAU$1.67
Margins
Gross margin is 60.08%, with operating margin of 32.75%, and net profit margin of 27.22%.
Gross Margin60.08%
Operating Margin32.75%
Pretax Margin32.60%
Net Profit Margin27.22%
EBITDA Margin37.37%
EBIT Margin32.79%
Analyst Forecast
The average price target for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is AU$49.21, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetAU$49.21
Price Target Upside29.81% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast11.99%
EPS Growth Forecast32.89%